SLC2A2 · rs5402
Strength of the evidence
Its strongest genetic-study result is p = 10−102, with 29 associations in the GWAS Catalog.
4: ClinVar disease-causing, reviewed by an expert panel or a guideline (3–4 stars). 3: ClinVar, several labs agreeing (2 stars), or a genetic study at p ≤ 10−50. 2: ClinVar from one lab (1 star), or p ≤ 10−20. 1: ClinVar submitted without criteria (0 stars), or genome-wide significance (p ≤ 5×10−8). The higher of the two counts. It says how solid the evidence is, not whether it matters for a particular person.
What the study found
Who was studied 98,316 European ancestry individuals.
The effect Each copy of the A allele shifted the measure 0.00161 higher (95% confidence interval 0.0011-0.0021); p = 7 × 10−10.
How common The A allele had a frequency of about 12% in the people studied.
Where it sits Chromosome 3, band 3q26.2 — at a splice region of SLC2A2.
What ClinVar records
Classification
Benign for Fanconi-Bickel syndrome; criteria provided, multiple submitters, no conflicts (2 of 4 stars, 8 submitters), last evaluated 2026-02-04.
ClinVar record 130350 NM_000340.2(SLC2A2):c.496+8A>T
Change history MyGeneLog™ keeps a copy of every weekly release from 2026-10-19 and compares them. This position's classification has not changed since.
What this is ClinVar's aggregate record for this position (as of its 2026-10-19 release), not a result about you. A classification describes the variant against the condition named, as laboratories submitted it. Whether a person carries this variant, and what that would mean for them, is a question for a clinical test and a genetic counsellor.
How common each version is
AT
A 0.5% · T 99.5%
A 0.4% · T 99.6%
A 0.4% · T 99.6%
A 2.2% · T 97.8%
A 0.9% · T 99.1%
A 22.2% · T 77.8%
A 21.8% · T 78.2%
A 23.8% · T 76.2%
The share of all copies of this position that are each version. Source: the population studies published in dbSNP (US NCBI); each row names its study.
rs5402 is a single position in the genome, in or near the SLC2A2 gene. Published research associates it with triglycerides in very small vldl. A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.
On MyGeneLog this position is linked to Age-Related Macular Degeneration. The research behind each link, and its sources, are set out on that condition page.
SLC2A2 carries pharmacogenomic findings for Metformin. That is educational information, not a prescription or a dosing guide. Any decision to start, stop or change a medicine belongs with the clinician or pharmacist managing your treatment.
No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.
GWAS Catalog, Ophthalmology science 2024, PMID:39091897. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.
Licensed CC BY-NC 4.0: free to read, share and adapt for non-commercial use, naming MyGeneLog™ and linking the exact page. Commercial use, including training or serving a commercial AI system, needs a licence — https://www.mygenelog.com/license
Triglycerides in very small VLDL (rs5402). MyGeneLog™. https://www.mygenelog.com/variants/rs5402